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MYH9-related disorder is an autosomal dominant disease caused by a mutation in the
MYH9 gene, which encodes nonmuscle myosin heavy chain IIA (NMMHC-IIA). This
disease is characterized by giant platelets, thrombocytopenia, granulocyte inclusion
bodies, proteinuria, and high-pitch sensorineural deafness. Nephropathy has been
observed in 30% of patients with MYH9-related disorder. The characteristic features are
early onset proteinuria and rapidly progressing renal disorder. However, the prognosis of
MYH9 nephropathy remains unclear. Herein, we describe a 36-year-old woman who
presented with proteinuria and was diagnosed with MYH9 nephropathy via renal biopsy
and gene analysis. Her proteinuria improved after administration of an angiotensin II
receptor blocker, but was aggravated after changing to a calcium channel blocker.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
MYH9-related disorder has been known as May-Hegglin
anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein
syndrome. Mutations in the MYH9 gene encoding the nonmuscle
myosin heavy chain IIA (NMMHC-IIA) have been identiﬁed in
these syndromes. The clinical features include sensorineural
hearing loss, cataract, and nephritis. The common laboratory
ﬁndings are autosomal dominant macrothrombocytopenia,
polymorphonuclear Döhle-like bodies, proteinuria, and elevated
creatinine levels. However, our understanding of the clinical
course and treatment of MYH9-related nephropathy is lacking,
especially in adult patients, because this disorder is very rare and
has been previously reported in young individuals [1,2].Case report
A 36-year-old Koreanwomanwas referred to our clinic because
of proteinuria that was incidentally detected at a local obstetrics15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
ersity Cheonan Hospital,
orea.clinic 9 months previously. At the age of 28 years, the patient was
diagnosed with thrombocytopenia, and she, along with her family
members, underwent hematological examinations. All other
family members were negative for thrombocytopenia. The patient
had no history of bleeding tendency. Since that time, no further
examination was performed.
At her ﬁrst visit to our clinic, her 24-hour urine analysis
showed proteinuria (926.0 mg/day; creatinine, 1,018 mg/day.
Blood chemistry ﬁndings revealed the following levels: blood)
urea nitrogen, 10.0 mg/dL; serum creatinine, 0.7 mg/dL; uric
acid, 5.3 mg/dL; total protein, 6.7 g/dL; and albumin, 4.1 g/dL. The
glomerular ﬁltration rate was 99.70 mL/min/1.73 m2. Hemato-
logical examination showed thrombocytopenia (46,000/mm3),
giant platelets, and Döhle bodies (Fig. 1). Ultrasonography did
not reveal any abnormalities in either of the kidneys.
We performed a renal biopsy. Renal biopsy specimens were
evaluated via light microscopy, immunoﬂuorescence microscopy,
and electron microscopy by using conventional techniques. On
light microscopy, four out of 26 total glomeruli showed global
sclerosis. Other glomeruli were unremarkable. Mild tubular
atrophy and interstitial ﬁbrosis were observed. On immunoﬂuor-
escence microscopy, no glomerular immune deposits were
detected. On electron microscopy, we observed severe podocytehrology. Published by Elsevier. This is an open access article under the
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deposits were absent, and glomerular basement membranes
(GBM) showed no structural abnormalities (Fig. 2). Before genetic
diagnosis was performed, otolaryngologists and ophthalmolo-
gists conducted audiometry and eye examinations, respectively.
No cataract was present, and the patient’s audiometry showed
high-pitch sensorineural hearing loss. Mutational analysis of the
MYH9 gene was performed for the patient and her sister. Entire
coding regions of the MYH9 gene were ampliﬁed via polymerase
chain reaction and directly sequenced. The gene analysis showed
a heterozygous c.5521G4A in exon 38 [p.Glu(GAG)1841Lys
(AAG)] in the patient [3], but not in her sister. We then identiﬁed
an MYH9 mutation (Fig. 3).
The laboratory ﬁndings regarding glomerular disease were as
follows: antinuclear antibody (–); antineutrophil cytoplasmicFigure 1. A peripheral blood smear. Giant platelets (arrows) and Döhle
bodies (arrow head) that appear as small, light blue/gray stained areas in
the cytoplasm of the neutrophil are shown (Wright staining, 1,000).
Figure 2. Renal biopsy ﬁndings. (A) On light microscopy, global sclerosis
(periodic acid–Schiff, 100). (B) On electron microscopy, partial podocyte fautoantibody (–); anti-dsDNA (–); anti-GBM antibody (–); hepa-
titis B surface antigen (–); antihepatitis B virus (–); antihepatitis C
virus (–); IgG, 1,214.9 mg/dL; IgA, 284.2 mg/dL; IgM, 88.6 mg/dL;
C3, 101.4 mg/dL; C4, 23.8 mg/dL; and CH50, 65.0 mg/dL. The
pattern of urine protein electrophoresis showed selective protei-
nuria and was glomerular in origin. The result of serum protein
electrophoresis was not remarkable.
The patient had two children, aged 16 years and 3 years;
both were delivered by normal spontaneous vaginal delivery.
Both children had thrombocytopenia. The ﬁrst child was lost to
follow-up, while the second continued to be followed up at
our clinic with no proteinuria detected as of this publication.
We followed up this patient for 2 years from her initial visit
to our clinic. She was ﬁrst administered an angiotensin II
receptor blocker (ARB) for 1 year. Then, the medication was
changed to amlodipine (calcium channel blocker; CCB)
because she was planning a pregnancy. The patient’s creati-
nine level remained in the 0.6–0.8 mg/dL range over 2 years.
However, the patient’s proteinuria decreased (224 mg/day)
during ARB treatment and increased (1,149.5 mg/day) during
CCB treatment (Fig. 4).Discussion
MYH9-related disorder is an autosomal dominant disease
caused by a mutation in the MYH9 gene. Nephropathy has been
detected in 30% of MYH9-related disorder cases (Table 1). Its
characteristic features are early onset proteinuria and rapidly
progressing renal disorder. Extrarenal manifestations include
hematological abnormalities (giant platelets, thrombocytopenia,
and leukocyte inclusions), cataracts, and sensorineural deafness.
MYH9-related nephropathy usually progresses to end stage
renal disease (ESRD) when a patient reaches his/her thirties.
However, our patient was diagnosed with MYH9-related
nephropathy when she was 36 years old, and she did not
show the rapid aggravation of renal failure observed inis observed on four of 26 glomeruli. Mild tubular atrophy is also seen
oot process effacement (arrows) is observed (2,500).
Figure 3. MYH9 mutational hot spot testing. (A) A heterozygous c.G5521A in exon 38 [p.Glu(GAG)1841Lys(AAG)] is evident in the patient. (B) Her
sister does not have the mutation.
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Figure 4. Proteinuria and serum creatinine over time. Proteinuria decreased during angiotensin II receptor blocker treatment and increased during
calcium channel blocker treatment. Serum creatinine remained stable during the follow-up.
Table 1. Summary of previous cases of adult onset MYH9 nephropathy diagnosed via renal biopsy
Age/sex Family history Proteinuria Macrothrombocytopenia Scr level at renal
biopsy (mg/dL)
Renal biopsy ﬁndings
36/Fn  þ þ 0.6 Global glomerulosclerosis, foot process
effacement
22/M [3] þ þ þ 0.8 Segmental glomerulosclerosis
49/M [4] þ þ þ 5.0 Glomerulosclerosis
24/F [4] þ þ þ 2.0 Foot process effacement
67/F [5]  þ N.D. 1.2 Focal global glomerulosclerosis
42/M [6]  þ N.D. 1.9 Segmental glomerulosclerosis, collapse
of individual tuft lobules
42/F [6]  þ N.D. 2.4 Segmental glomerulosclerosis, collapse
of individual tuft lobules
n The present case.
N.D., no data; Scr, serum creatinine.
Oh et al / MYH9 nephropathy 55previous case reports. Because of her mild symptoms, this
patient’s diagnosis may have been delayed.
Proteinuria in MYH9-related nephropathy may be due to
foot process effacement of the renal podocyte. Arrondel et al[1] described a high expression of MYH9 in mature kidneys
and showed that NMMHC IIA was mainly present on podo-
cytes. Further analysis of the D1424N domain substitution in
MYH9 revealed atypical distribution of NMMHC IIA in tubular
Kidney Res Clin Pract 34 (2015) 53–5656epithelia, focal and segmental effacement of podocytes, and
cosegregation of a speciﬁc podocin haplotype [1,2].
Few studies have described patients with MYH9-related
nephropathy that was detected while the patient was an adult.
Pecci et al [7] reported that 61 of 247 evaluable patients (25%)
developed proteinuric nephropathy, and the mean age at onset
was 27 years; in addition, 72% of the patients were diagnosed
prior to the age of 35 years. This study included consecutive
patients enrolled in the Italian Registry for MYH9-RD as of
March 2012. However, there are no data relating to renal
biopsy ﬁndings in that article.
Han et al [3] described a case of MYH9 nephropathy proven
via biopsy, with detected renal involvement, when the patient
was 22 years old; he had persistent proteinuria, but no further
deterioration was observed in renal function for 416 years
after the renal involvement was ﬁrst detected. As previously
mentioned, MYH9-related nephropathy usually progresses to
ESRD when the patient reaches his/her thirties. Because rapid
deterioration in renal failure was not observed in this patient,
it is an interesting case.
MYH9-related disorder and MYH9 nephropathy are rare.
Therefore, reliable data on the prevalence are lacking. However,
MYH9 nephropathy may need to be considered if a patient
shows thrombocytopenia, proteinuria, and megakaryocyte.
Historically, therapeutic options to slow the progression to
ESRD in patients with MYH9-related nephropathy have been
lacking. Regarding treatment, blockade of the renin–angiotensin
system through the administration of angiotensin-converting
enzyme inhibitors or ARBs seems to decrease proteinuria and
preserve renal function, perhaps owing to the direct effects of
these agents on podocytes [8,9]. In our case, a CCB did not seem
to decrease proteinuria.
In summary, we describe a 36-year-old woman with pro-
teinuria due to an MYH9 disorder who showed a mild disease
course and whose proteinuria responded to treatment with an
ARB but not a CCB. Further investigations regarding the role of
the MYH9 gene in renal injury caused by MYH9 disorders are
needed.Conﬂict of interest
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